^
    Back
    Association details:
    Biomarker:PTEN underexpression
    Cancer:Chronic Myeloid Leukemia
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR 2020
    Title:

    Abstract 4682: Influence of PI3K/AKT pathway on imatinib mesylate treatment outcome in chronic myeloid leukemia patients

    Published date:
    06/23/2020
    Excerpt:
    However, with respect to the clinical phase and imatinib response, none of the genes showed significant differences except for PTEN, which was significantly downregulated in advanced phase (p<0.042) and in cases with poor imatinib response.
    DOI:
    10.1158/1538-7445.AM2020-4682